Результаты поиска

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.

OBJECTIVES: The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation. TRIAL DESIGN: The OVID study is conducted as a multicentre open-label superiority randomised controlled trial. PARTICIPANTS: Inclusion Criteria 1. Signed patient informed consent after being fully informed about the study's background. 2. Patients aged 50 years or older wit

Evaluation of transfusion pyrexia: a review of differential diagnosis and management.

Background/purpose. Transfusion pyrexia (fever) is an important clinical sign/symptom occurring either as an isolated event or as part of a constellation of signs and symptoms in relation to blood transfusion. It is an important cause of morbidity and may be an important sign of life-threatening complications of blood transfusion. Pyrexia is often a reason for the discontinuation of a blood transfusion episode, and adequate evaluation remains a challenge for clinicians. The decision to stop a blood transfusion episode on account of fever is often a difficult one. This paper reviews the differe

Совпадение в полном тексте источника
… Febrile responses have also been reported as being more common in patients receiving platelet transfusions than red cell transfusion [ 14 ]. … transfusions. …

Poster Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… The use of apheresis platelets now exceeds the use of pooled random-donor platelets; however, use of this product in emergency situations is limited by the availability of volunteer donors. 35 Indications for Platelet Transfusion Platelet transfusions are indicated for patients bleeding because of … Prophylactic platelet transfusion for thrombocytopenia secondary to underproduction remains controversial. …

Запоздалое переливание после лечения CART связано с стойкой гематотоксичностью и безвозвратной смертностью во многих миеломах: постспециальный анализ.

ЦЫПЛЕНОК: Химерическая антигенная рецепторная T-клетка (CAR-T-клетка) весьма эффективна для повторной/рефракторной множественной миеломы (R/R MM), однако гематологическая токсичность и потребность в переливании крови остаются распространенными явлениями. В ходе этого исследования были изучены модели потребностей в переливании у пациентов, получающих клеточную терапию CAR-T, проанализированы факторы риска и оценены последствия переливания для клинических результатов. МЕТОДЫ: Это ретроспективное исследование включало 155 Пациенты ОРМ лечатся клетками ЦАР-Т, направленными против различных антиген

Совпадение в полном тексте источника
… L Association between total platelet transfusion and overall survival. … L Association between total platelet transfusion and overall survival. …

Poster Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… transfusions. … Low pre-transfusion platelet counts (<20,000/µL) predicted higher platelet transfusions which was statistically significant (p<0.001). For PRBC transfusions, 55 patients were transfused with pre-transfusion hemoglobin (<7 g/dL). …

Haematological Diseases in the Tropics

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients.

Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difficulties arise when Jehovah's Witness patients refuse blood transfusions. In order to demonstrate the safety of performing "bloodless" ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and 1

Совпадение в полном тексте источника
… In the course of ASCT it is customary to provide red cell and platelet transfusion support on a preventative basis. Most institutions recommend red cell transfusion for hemoglobin levels < 7 g/dL, and platelet transfusion for platelet counts < 10 × 10 9 /L. … with the platelet transfusion-free approach [ 19 ]. …

Poster

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Background : Platelet transfusions are widely used to treat thrombocytopenia of various etiology. There are two different methods of preparation of platelet concentrate from whole blood, one is Platelet-rich plasma method (PRP) and the Buffy Coat Removed (BCR) method. … Conclusion : On the basis of count increment, corrected count increment, percent platelet recovery and incidence of post transfusion reactions, BCR platelet transfusions showed a better outcome than PRP platelet transfusions. …

Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.

IntroductionTransfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution.MethodsThe clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009-2020). Fo

Совпадение в полном тексте источника
… Red cell and platelet transfusion burden following myeloablative allogeneic haematopoietic stem cell transplantation. Intern. Med. J. 2015;45:1286–1292. doi: 10.1111/imj.12894. 19. … Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant. Transfusion. 2020;60:2225–2242. doi: 10.1111/trf.15961. 25. …

The impact of myelosuppression on quality of life of patients treated with chemotherapy.

Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thrombocytopenia can lead to fear and anxiety. However, traditional interventions for myelosuppression fall short of the ideal. Granulocyte colony-stimulating factors reduce the risk of severe neutropenia but commonly lead to bone pain. Erythropoiesis-stimulating agents are not always effective and may cause thromboembolic events, while transfusi

Совпадение в полном тексте источника
… Platelet transfusions are also associated with a risk of infection due to bacterial contamination [ 49 , 90 ]. … Platelet transfusion: a clinical practice guideline from the AABB. Ann. Intern. Med. 2015;162(3):205–213. doi: 10.7326/M14-1589 90. Kiefel V. Reactions induced by platelet transfusions. Transfus Med. Hemother. 2008;35(5):354–358. doi: 10.1159/000151350 91. George JN, Mathias SD, Go RSet al. …

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Note that platelet transfusions are not effective in ITP and may worsen TTP/HUS and HITT TREAT UNDERLYING CAUSE — discontinue medications that may cause thrombocytopenia (platelets may return to normal in 14–21 days). … Platelet transfusions may also provide temporary support for actively bleeding patients second line — splenectomy , with platelet recovery within 2 weeks in 2/3 of patients. …

What are safe hemoglobin, neutrophil and platelet counts for people with hematological malignancies to participate in exercise and activities of daily living: a scoping review.

PurposeThe aim of this scoping review was to summarize the extent of the literature in relation to safe levels of platelet, hemoglobin and neutrophil count for people with hematological cancers to participate in exercise or activities of daily living (ADLs).MethodsA comprehensive search for this scoping review was completed in July 2024 across five databases: the Cochrane Library, Embase, PEDro, PubMed and OTSeeker. Original studies, reviews and expert opinion papers were included if they focused on people with active hematological cancer diagnoses or those undergoing treatment affecting bone

Совпадение в полном тексте источника
… Therapy should be in the patients room with equipment cleaned before and after use | N/A Jeevanantham et al. 2021 [ 45 ] Systematic review and expert consensus | Therapists: 10 Patients: 10 17 critically appraised articles Patient cohort: multiple myeloma | Platelet: < 10: platelet transfusion, essential … One study reported a platelet transfusion was required if participants platelet value were < 15 × 10 9 /L; however, exercise and activity were not withheld awaiting this [ 29 ]. …

Safety of rehabilitation interventions for patients with hematologic diseases associated with low blood counts-verification focusing on blood cancer.

[Purpose] This study aimed to establish unique criteria for hematologic patients with low blood counts in the borderline region of or below the threshold for discontinuing cancer rehabilitation without meeting the criteria for blood transfusion, and to investigate the physical symptoms and activities of daily living. [Participants and Methods] Among the 251 participants, 128 had blood test results below the discontinuation criteria. They were permitted to engage in rehabilitation interventions by a hematologist based on the new criteria. The remaining 123 patients were classified under the dis

Совпадение в полном тексте источника
… Estcourt LJ, Stanworth SJ, Murphy MF: Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol, 2011, 154: 425–440. 19. Buhrkuhl DC: An update on platelet transfusion in hematooncology supportive care. Transfusion, 2010, 50: 2266–2276. 20. … . : Evaluation of platelet transfusion threshold in patients with acute leukemia receiving induction chemotherapy. Jpn J Transfus Cell Ther, 2009, 55: 589–595. 21. Oka S, Haraike S, Kawano T, et al. : Evaluation of platelet transfusion triggers in hematopoietic stem cell transplant patients. …

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from anticancer medications and represents an important limitation for the use of antithrombotic treatments, including anticoagulant, antiplatelet, and fibrinolytic agents. These drugs are often required for prevention or treatment of cancer-associated thrombosis or for cardioembolic prevention in atrial fibrillation in an increasingly older cancer population. Data indicate that cancer remains an independent risk factor for thrombosis even in case of thrombocytopenia, since mild-to-moderate thrombocytopenia does n

Совпадение в полном тексте источника
… procedures with a high-bleeding risk, higher platelet transfusion thresholds (generally ≥50 × 10 9 /L) are recommended. 62 Although this is a relatively common practice, the efficacy and safety of increased platelet transfusion thresholds/targets, while on therapeutic anticoagulation is not proven. … Use of platelet transfusion a. Grade 3–4 TP: i. Platelet transfusion with a target of 40–50 × 10 9 /L together with therapeutic-dose LMWH, if the platelet target is achieved, may be considered in patients with very-high-thrombotic risk* for a maximum of 14 days. …

Rehabilitation intervention safety in patients with malignant lymphoma with low blood cell counts.

[Purpose] We established criteria for patients with malignant lymphoma with low blood counts, who did not meet the criteria to discontinue rehabilitation or the blood transfusion criteria even though they were borderline for discontinuing rehabilitation. We investigated physical symptoms, activities of daily living, and adverse events in patients who were permitted to undergo rehabilitation intervention using the new criteria. [Participants and Methods] Forty-two patients met the criteria to discontinue rehabilitation based on blood data, and the new-criteria group included 153 patients who re

Совпадение в полном тексте источника
… AABB: Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med, 2015, 162: 205–213. 17. Estcourt LJ, Stanworth SJ, Murphy MF: Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol, 2011, 154: 425–440. 18. … Buhrkuhl DC: An update on platelet transfusion in hematooncology supportive care. Transfusion, 2010, 50: 2266–2276. 19. Schiffer CA, Bohlke K, Delaney M, et al. : Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. …

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these

Совпадение в полном тексте источника
… We recommend a phased response for platelet transfusions on the basis of the estimation of available blood bank resources. … If platelet availability is reduced, initial strategies to conserve platelet stocks include avoiding prophylactic platelet transfusions for surgical interventions by deferring non-urgent procedures and establishing an inpatient and outpatient threshold for prophylactic platelet transfusions of less than …

Acquired platelet disorders.

Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most re

Совпадение в полном тексте источника
… Platelet transfusion is typically reserved for major bleeding or before emergency/urgent procedures. … Liver disease-related TP : In patients with severe TP undergoing invasive procedures, platelet transfusion is the mainstay of therapy. …

A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration.

BackgroundPatients receiving a variety of chemotherapy regimens often develop chemotherapy-induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is as

Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review.

BACKGROUND: Patients with cancer-associated thrombosis (CAT) are at an increased risk of recurrent thrombosis and bleeding, especially if there is treatment- or disease-related thrombocytopenia. While direct oral anticoagulants (DOACs) are used in the management of CAT, low molecular weight heparin (LMWH) continues to be recommended for CAT with thrombocytopenia. OBJECTIVES: This study aimed to identify the rates of recurrent venous thromboembolism (VTE) and bleeding in patients with CAT and thrombocytopenia treated with DOACs compared with LMWH. METHODS: A retrospective review of patients w

Совпадение в полном тексте источника
… No platelet transfusion-related complications were documented within the 90-day follow-up period. Table 3 Platelet transfusion data. … 3.2 2.4 38 Table 3 Platelet transfusion data. …